Not yet recruiting
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
NCT07791732· Phase 3· Daiichi Sankyo· Source
Not yet recruiting
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· Phase 2· UNICANCER· Source
Recruiting
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source
Not yet recruiting
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
2024-520140-42-00· Phase 3· Institut Gustave Roussy· Source
Recruiting
Early detection of triple negative breast cancer relapse (CUPCAKE)
2022-501562-22-01· Phase 2· Institut Curie· Source
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· Phase 3· AstraZeneca· Source
Recruiting
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients
NCT06846346· Phase 2· Unicancer· Source
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· Phase 3· AstraZeneca· Source
Recruiting
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· Phase 3· UNICANCER· Source
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a multicentre phase II randomized trial (PIPOX02)
2024-514560-10-00· Phase 2· Institut De Cancerologie De L Ouest· Source
Recruiting
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· Phase 3· UNICANCER· Source
Recruiting
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT06245356· Phase 2· UNICANCER· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485· Phase 3· Celgene· Source
Recruiting
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· Phase 2· UNICANCER· Source
Recruiting
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.
2022-501315-13-00· Phase 3· Centre Leon Berard· Source
Recruiting
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)
2023-503326-39-00· Phase 3· Institut Gustave Roussy· Source
Recruiting
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· Phase 3· Amgen Inc.· Source
Recruiting
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT06725368· Phase 2· Centre Paul Strauss· Source
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
2023-503675-24-00· Phase 3· AstraZeneca AB· Source
Active, not recruiting
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
NCT06715241· Phase 2· ARCAGY/ GINECO GROUP· Source
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· Phase 3· UNICANCER· Source
Recruiting
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
NCT05168839· Phase 4· Centre Hospitalier Regional Universitaire· Source
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· Phase 3· Gilead Sciences· Source
Recruiting
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI
2023-505298-34-00· Phase 2· Unicancer· Source
Recruiting
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
NCT06195709· Phase 3· Institut Curie· Source
Recruiting
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· Phase 3· AstraZeneca· Source
Active, not recruiting
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT05856695· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326· Phase 2· Genentech, Inc.· Source
Recruiting
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06))
2023-505040-19-00· Phase 2· Institut Gustave Roussy· Source
Active, not recruiting
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
NCT05219318· Phase 3· University Hospital, Bordeaux· Source
Recruiting
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
NCT05200481· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
2024-518244-20-01· Phase 2· Queen Mary University Of London· Source
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· Phase 3· UNICANCER· Source
Active, not recruiting
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast Cancer
NCT04784714· Phase 3· AstraZeneca AB· Source
Active, not recruiting
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
NCT03806309· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source
Active, not recruiting
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT04621188· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Active, not recruiting
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease: chemotherapy and combination of hormonotherapy with abemaciclib.
NCT04158362· Phase 3· Unicancer· Source
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
NCT03875781· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
NCT03842982· Phase 3· Centre Oscar Lambret· Source
Active, not recruiting
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT03697850· Phase 2· UNICANCER· Source
Active, not recruiting
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source
Showing 50 of 57.